AIM
AIM ImmunoTech Inc. (AIM) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Negative ROIC is materially better than peers with persistent capital destruction, because AIM still appears to preserve some invested-capital discipline relative to weaker microcap comparables.
A very negative cash conversion cycle indicates supplier-funded working capital, which can support liquidity and operating flexibility better than peers with cash-consuming models.
Current and quick ratios above 2.0 suggest short-term balance-sheet resilience, leaving AIM better positioned than leveraged peers to absorb near-term volatility.
Weaknesses
TTM ROIC of -94.8% signals severe value destruction, leaving AIM structurally behind profitable peers that compound capital at positive returns.
Net debt to EBITDA remains positive and debt-to-equity is above 0.5, so leverage is less conservative than peers with net-cash or lower-debt profiles.
The absence of disclosed margin data limits evidence of operating efficiency, but the negative return profile still implies weaker economics than peers.
Opportunities
A negative cash conversion cycle can be scaled if growth improves, because working-capital efficiency may free cash faster than peers with longer collection cycles.
Liquidity above 2.0 provides room to fund restructuring or selective investment, which can improve positioning versus peers constrained by tighter balance sheets.
If capital allocation improves, AIM could narrow the ROIC gap versus peers, since even modest earnings recovery would materially lift a deeply negative base.
Threats
Persistently negative ROIC creates a compounding disadvantage, because peers with positive returns can reinvest while AIM continues eroding shareholder capital.
Any tightening in credit conditions would matter more for AIM than for peers with stronger balance sheets, given its still-positive leverage metrics.
Without visible margin support, AIM remains exposed to competitive pricing pressure, which can keep it behind peers with structurally higher profitability.
Overall Score
AIM’s structural positioning versus peers is weak overall, as severe capital destruction outweighs its liquidity and working-capital advantages.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on AIM ImmunoTech Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
